Krystal Biotech, Inc.
KRYS · Healthcare
$363.84
Φόρτωση γραφήματος…
Νέα
Τελευταίοι τίτλοι για αυτή τη μετοχή
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Krystal Biotech announced its participation in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will participate in a fireside chat at 3:55 pm ET and host investor meetings. The company reported strong Q2 2026 results with $119.2 million in VYJUVEK global revenue and $965.9 million in cumulative revenue since launch, with plans for European expansions and multiple clinical data readouts expected in the second half of 2026.
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
Krystal Biotech shares have gained 12% since its last earnings report, outperforming the S&P 500. The company beat Q2 2026 earnings estimates with EPS of $1.79 vs. consensus of $1.70, and revenues of $119.2 million from Vyjuvek sales grew 24% year-over-year. Despite upward estimate revisions, the stock holds a Zacks Rank #3 (Hold) with an overall VGM Score of D, suggesting in-line returns ahead.